Anti-Fbxo7 [HLA3]

Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed.

Contributors

Inventor Institute
Heike Laman University College London (UCL)
SKU: 151883
Product description: Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed. These cell lines all express Fbxo7: U2OS, SHSY5Y, HEK293, Jurkat, SKOV3, HeLa, Ba-F3, Nalm6, C33A, MEL, HSPCs, MEFs.
Conjugation: Unconjugated
Molecular weight: ~59/~70 kDa
Immunogen: aa 499-522 of human Fbxo7 synthetic peptide coupled to KLH
Cat. #: 151883
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cell biology;Genetics
Application: IHC ; IP ; WB
Target: Fbxo7
Reactivity: Human ; Mouse
Clone: HLA3
Host: Rabbit
Class: Polyclonal
Target background: Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed. These cell lines all express Fbxo7: U2OS, SHSY5Y, HEK293, Jurkat, SKOV3, HeLa, Ba-F3, Nalm6, C33A, MEL, HSPCs, MEFs.
Format: Liquid
Shipping conditions: Dry ice
References:

Burchell et al. 2013. Nat Neurosci. 16(9):1257-65. PMID: 23933751.

The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.

Meziane el et al. 2011. J Cell Sci. 124(Pt 13):2175-86. PMID: 21652635.

Knockdown of Fbxo7 reveals its regulatory role in proliferation and differentiation of haematopoietic precursor cells.

Laman et al. 2005. EMBO J. 24(17):3104-16. PMID: 16096642.

Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151016 Anti-CyclinA [E72.1] Key Info View Tool
151019 Anti-Mos [S3.1] Key Info View Tool
151025 Anti-Vascular endothelium [10] Key Info View Tool
151033 Anti-HSVUL42 [13C9] Key Info View Tool
151026 Anti-FCGR1 [10.1] mAb Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.